Head of Translational Oncology Research Unit Translation Research Coordinator CTC IFO/IRE
IRCSS Regina Elena National Cancer Institute, Rome, ITALY

Head and Neck Cancer: an evolving tumor entity

Host: S. Zacchigna

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with 890,000 new cases and 450,000 deaths in 2018. The incidence of HNSCC continues to rise and is anticipated to increase by 30% (that is 1.08 million new cases annually) by 2030 (Global Cancer Observatory (GLOBOCAN). Most patients present with a locally advanced disease with a high risk of recurrence, and approximately 10% of them presents with a metastatic disease. The 5-year survival for HNSCC patients across all stages is ~40%–50% while the median overall survival for recurrent/metastatic (R-M) patients is 10–14 months only.

There is a tremendous need to identify molecular biomarkers that can be used to predict progression of pre-malignant HNSCC lesions, prognosticate survival, reveal new targets for intervention and predict response to therapeutic agents.


Hundreds of videos, tens of playlists providing free scientific content worldwide